» Articles » PMID: 20443882

Challenges and Standards in Reporting Diagnostic and Prognostic Biomarker Studies

Overview
Journal Clin Transl Sci
Date 2010 May 7
PMID 20443882
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The discovery of novel biomarkers is a crucial goal in translational biomedical research. A complete and accurate reporting of biomarker studies, including quantitative prediction models, is fundamental to improve research quality and facilitate their potential incorporation into clinical practice. This paper reviews key problems, guidelines, and challenges in reporting biomarker studies, with an emphasis on diagnostic and prognostic applications in cardiovascular research. Recent advances and recommendations for aiding in peer review, research quality assessment, and the reproducibility of findings, such as diagnostic biosignatures, are discussed. An examination of research recently published in the area of cardiovascular biomarkers was implemented. Such a survey, which was based on a sample of papers deposited in PubMed Central, suggests that there is a need to improve the documentation of biomarker studies in terms of information completeness and clarity, as well as the application of more rigorous quantitative evaluation techniques. There is also room for improving practices in reporting data analysis and research limitations. This survey also suggests that, in comparison with other research areas, the cardiovascular biomarker research domain may not be taking advantage of existing standards for reporting diagnostic accuracy. The review concludes with a discussion of the challenges and recommendations.

Citing Articles

Insights on the Biomarker Potential of Exosomal Non-Coding RNAs in Colorectal Cancer: An In Silico Characterization of Related Exosomal lncRNA/circRNA-miRNA-Target Axis.

Mezher M, Abdallah S, Ashekyan O, Shoukari A, Choubassy H, Kurdi A Cells. 2023; 12(7).

PMID: 37048155 PMC: 10093117. DOI: 10.3390/cells12071081.


Systematic review of preterm birth multi-omic biomarker studies.

Gupta J, Alfirevic A Expert Rev Mol Med. 2022; :1-24.

PMID: 35379367 PMC: 9884789. DOI: 10.1017/erm.2022.13.


Heat Shock Factor 1 as a Prognostic and Diagnostic Biomarker of Gastric Cancer.

Kim W, Kim S Biomedicines. 2021; 9(6).

PMID: 34064083 PMC: 8224319. DOI: 10.3390/biomedicines9060586.


A systematic review on metabolomics-based diagnostic biomarker discovery and validation in pancreatic cancer.

Long N, Yoon S, Anh N, Nghi T, Lim D, Hong Y Metabolomics. 2019; 14(8):109.

PMID: 30830397 DOI: 10.1007/s11306-018-1404-2.


[Inappropriate test methods in allergy].

Kleine-Tebbe J, Herold D Hautarzt. 2010; 61(11):961-6.

PMID: 20963379 DOI: 10.1007/s00105-010-1969-9.

References
1.
Arab S, Gramolini A, Ping P, Kislinger T, Stanley B, Van Eyk J . Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol. 2006; 48(9):1733-41. DOI: 10.1016/j.jacc.2006.06.063. View

2.
Kostka D, Spang R . Microarray based diagnosis profits from better documentation of gene expression signatures. PLoS Comput Biol. 2008; 4(2):e22. PMC: 2242819. DOI: 10.1371/journal.pcbi.0040022. View

3.
Wang Y, Barbacioru C, Shiffman D, Balasubramanian S, Iakoubova O, Tranquilli M . Gene expression signature in peripheral blood detects thoracic aortic aneurysm. PLoS One. 2007; 2(10):e1050. PMC: 2002514. DOI: 10.1371/journal.pone.0001050. View

4.
Moher D, Cook D, Eastwood S, Olkin I, Rennie D, Stroup D . Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999; 354(9193):1896-900. DOI: 10.1016/s0140-6736(99)04149-5. View

5.
Smidt N, Rutjes A, van der Windt D, Ostelo R, Bossuyt P, Reitsma J . Reproducibility of the STARD checklist: an instrument to assess the quality of reporting of diagnostic accuracy studies. BMC Med Res Methodol. 2006; 6:12. PMC: 1522016. DOI: 10.1186/1471-2288-6-12. View